$161.78 Million in Sales Expected for Repligen Co. (NASDAQ:RGEN) This Quarter

Wall Street analysts expect that Repligen Co. (NASDAQ:RGEN) will post sales of $161.78 million for the current quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Repligen’s earnings, with the highest sales estimate coming in at $166.80 million and the lowest estimate coming in at $144.40 million. Repligen posted sales of $94.06 million during the same quarter last year, which indicates a positive year over year growth rate of 72%. The firm is expected to issue its next earnings report on Thursday, November 4th.

According to Zacks, analysts expect that Repligen will report full year sales of $632.28 million for the current year, with estimates ranging from $577.30 million to $644.90 million. For the next fiscal year, analysts anticipate that the company will post sales of $747.47 million, with estimates ranging from $725.00 million to $784.90 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Repligen.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Monday, July 26th. The biotechnology company reported $0.79 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.52 by $0.27. Repligen had a return on equity of 9.21% and a net margin of 19.65%. The firm had revenue of $162.96 million during the quarter, compared to the consensus estimate of $144.24 million. During the same quarter in the previous year, the business earned $0.42 earnings per share. The firm’s quarterly revenue was up 86.3% compared to the same quarter last year.

RGEN has been the subject of a number of research reports. KeyCorp boosted their price target on Repligen from $255.00 to $335.00 and gave the company an “overweight” rating in a research report on Friday. Stephens upped their target price on Repligen from $255.00 to $290.00 and gave the stock an “overweight” rating in a research report on Friday, August 20th. Finally, Craig Hallum upped their target price on Repligen from $251.00 to $258.00 and gave the stock a “buy” rating in a research report on Wednesday, July 28th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Repligen presently has a consensus rating of “Buy” and an average target price of $262.17.

In related news, Director Thomas F. Ryan, Jr. sold 780 shares of the business’s stock in a transaction dated Wednesday, August 4th. The stock was sold at an average price of $250.50, for a total value of $195,390.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Karen A. Dawes sold 4,585 shares of the business’s stock in a transaction dated Tuesday, July 20th. The stock was sold at an average price of $202.09, for a total value of $926,582.65. The disclosure for this sale can be found here. Insiders sold 52,154 shares of company stock valued at $14,144,680 in the last ninety days. Company insiders own 1.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in RGEN. Amundi Pioneer Asset Management Inc. acquired a new stake in Repligen during the first quarter valued at approximately $2,925,000. Commonwealth Equity Services LLC raised its stake in Repligen by 23.7% during the first quarter. Commonwealth Equity Services LLC now owns 14,332 shares of the biotechnology company’s stock valued at $2,786,000 after buying an additional 2,749 shares in the last quarter. Envestnet Asset Management Inc. raised its stake in Repligen by 12.5% during the first quarter. Envestnet Asset Management Inc. now owns 31,304 shares of the biotechnology company’s stock valued at $6,086,000 after buying an additional 3,481 shares in the last quarter. Cullen Frost Bankers Inc. raised its stake in Repligen by 16.3% during the first quarter. Cullen Frost Bankers Inc. now owns 465 shares of the biotechnology company’s stock valued at $90,000 after buying an additional 65 shares in the last quarter. Finally, Institutional & Family Asset Management LLC raised its stake in Repligen by 1,900.0% during the first quarter. Institutional & Family Asset Management LLC now owns 200 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 190 shares in the last quarter. Hedge funds and other institutional investors own 83.82% of the company’s stock.

RGEN stock opened at $306.90 on Friday. The stock has a 50-day moving average price of $254.76 and a two-hundred day moving average price of $215.50. Repligen has a 12-month low of $138.00 and a 12-month high of $310.69. The company has a market cap of $16.85 billion, a PE ratio of 171.45 and a beta of 0.90.

About Repligen

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs.

Read More: What are earnings reports?

Get a free copy of the Zacks research report on Repligen (RGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.